About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
C
How To Cure The Very High Risk Childhood ALL? Dasatinib vs. Imatinib & Combination Venetoclax and Navitoclax in R/R
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Ching-Hon Pui
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Ching-Hon Pui
6 views
October 16, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Meet The Professor Sessions
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351
Feat.
M. Mauro
18:04
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Biomarkers To Predict Treatment Free Remission in CML – Can We Predi…
Feat.
T. Hughes
19:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Management of Advanced Phase CML: Treatment Options for Accelerated…
Feat.
E. Jabbour
14:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Where do Immunotherapies Fit in the Treatment Landscape of ALL?
Feat.
P. Kebriaei
14:33
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
How To Cure The Very High Risk Childhood ALL? Dasatinib vs. Imatinib…
Feat.
C. Pui
15:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Future of Frontline ALL in Adults: Complex Biological Work up an…
Feat.
N. Boissel
14:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Harnessing the Immune System for Treating AML: Targeting CD33 and IL…
Feat.
F. Ravandi
15:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
IDH Inhibitor Therapy in AML: Ivosidenib & Enasidenib Mono and C…
Feat.
C. DiNardo
10:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Manipulating Microenvironment to Overcome Chemotherapy Resistance in…
Feat.
D. DeAngelo
22:31
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Identification and Management of Patients with Polycythemia Vera and…
Feat.
S. Verstovsek
15:43
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Combination Approaches With Ruxolitinib in Primary Myelofibrosis - W…
Feat.
N. Pemmaraju
13:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Identification and Management of Ruxolitinib Failure in Myelofibrosi…
Feat.
L. Masarova
10:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treat…
Feat.
K. Dunleavy
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Role of Venetoclax in DLBCL: Efficacy and Safety Results from th…
Feat.
A. Zelenetz
11:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin…
Feat.
A. Moskowitz
31:49
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
From CHIP, ICUS, and CCUS to Myelodysplastic Syndromes: Disease Stat…
Feat.
L. Godley
20:22
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Lower Risk Myelodysplastic Syndromes Management: Overview of the Cur…
Feat.
R. Komrokji
25:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Higher Risk Myelodysplastic Syndromes Management: Overview of the C…
Feat.
V. Santini
09:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal an…
Feat.
A. Krishnan
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/R…
Feat.
M. Dimopoulos
17:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Epigenetic Mechanisms in CLL: Inter- and Intra-Patient Heterogeneity…
Feat.
D. Rossi
19:03
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Mechanisms of Resistance in CLL to Targeted Agents: Could We Use The…
Feat.
P. Ghia
18:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Genomic Complexity of CLL: Complex Karyotype, Cytogenetic Complexity…
Feat.
R. Brandell
